Company profile: Iridia
1.1 - Company Overview
Company description
- Provider of nanotechnology solutions that embed synthetic DNA molecules into products to deliver authenticity, traceability, and data infusion. Offers a Molecular Avatar Technology platform for supply chain transparency, embedding data directly into materials, enabling personalized information and Web3-enabled utilities for enhanced customer engagement, and art authentication to ensure provenance.
Products and services
- Authenticity: A forensic-grade service that delivers verifiable, unique molecular identities embedded in products using synthetic DNA, ensuring genuine provenance and deterring counterfeiting across diverse materials
- Molecular Avatar Technology: A nano-scale platform that embeds synthetic DNA molecules and nanotechnology into products, enabling authenticity, supply-chain traceability, and direct data infusion into materials
- Traceability: An end-to-end system that architects supply-chain transparency by tracking the journey of materials or products from production to end-user using embedded molecular identities
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Iridia
ReadCoor
HQ: United States
Website
- Description: Provider of the first true spatial multi-omic platform (RC2) that simultaneously detects and reads sequences, serving a global audience of researchers, clinicians, pharma and diagnostics companies to expand understanding of human biology and facilitate the creation of new therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ReadCoor company profile →
Rome Therapeutics
HQ: United States
Website
- Description: Provider of novel therapies for cancer and autoimmune diseases harnessing the repeatome, including development of LINE-1 reverse transcriptase inhibitors for autoimmune diseases, supported by a data science platform that identifies active elements in the dark genome and assesses their roles in disease to guide drug development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rome Therapeutics company profile →
Immuneering
HQ: United States
Website
- Description: Provider of bioinformatics-driven drug discovery developing investigational medicines, including IMM-1-104 targeting RAS-mutant advanced solid tumors with once-daily oral dosing, and IMM-6-415, a Deep Cyclic Inhibitor for RAF or RAS-mutant advanced solid tumors with twice-daily dosing; also maintains an Expanded Access Policy (not currently available).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immuneering company profile →
Genable Technologies
HQ: Ireland
Website
- Description: Provider of gene medicines to treat "dominant" genetic diseases, developed by a privately held, venture backed, Dublin (Ireland) based bio-pharmaceutical company, based on the pioneering work of Professor Jane Farrar, Dr Paul Kenna & Professor Peter Humphries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genable Technologies company profile →
ExpreS2ion Biotechnologies
HQ: Denmark
Website
- Description: Provider of innovative vaccines and the human clinical Phase III-validated ExpreS2™ technology platform for fast and efficient development of novel, life-saving vaccines that improve quality of life worldwide.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ExpreS2ion Biotechnologies company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Iridia
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Iridia
2.2 - Growth funds investing in similar companies to Iridia
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Iridia
4.2 - Public trading comparable groups for Iridia
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →